User login
Key clinical point: Patients with psoriatic arthritis (PsA) are more likely to have additional medical conditions beyond skin and joints than those with psoriasis alone.
Major finding: During follow-up, 12% of patients had an indication for PsA. Rates of comorbidities like hypertension, hyperlipidemia, fatigue, diabetes, chronic pulmonary disease, obesity, cardiovascular disease, depression, and anxiety were at least 1.1-1.7 times higher in the psoriasis-PsA vs. psoriasis-only group.
Study details: This was a retrospective study of 19,333 patients with prevalent psoriasis with no prior evidence of PsA from the United States.
Disclosures: The study was funded by UCB Pharma. R Suruki and E Lee declared being employees and shareholders of UCB Pharma. M Skornicki, P Prince, and A Louder declared being employees of Aetion Inc.
Source: Skornicki M et al. Adv Ther. 2021 Apr 5. doi: 10.1007/s12325-021-01698-7.
Key clinical point: Patients with psoriatic arthritis (PsA) are more likely to have additional medical conditions beyond skin and joints than those with psoriasis alone.
Major finding: During follow-up, 12% of patients had an indication for PsA. Rates of comorbidities like hypertension, hyperlipidemia, fatigue, diabetes, chronic pulmonary disease, obesity, cardiovascular disease, depression, and anxiety were at least 1.1-1.7 times higher in the psoriasis-PsA vs. psoriasis-only group.
Study details: This was a retrospective study of 19,333 patients with prevalent psoriasis with no prior evidence of PsA from the United States.
Disclosures: The study was funded by UCB Pharma. R Suruki and E Lee declared being employees and shareholders of UCB Pharma. M Skornicki, P Prince, and A Louder declared being employees of Aetion Inc.
Source: Skornicki M et al. Adv Ther. 2021 Apr 5. doi: 10.1007/s12325-021-01698-7.
Key clinical point: Patients with psoriatic arthritis (PsA) are more likely to have additional medical conditions beyond skin and joints than those with psoriasis alone.
Major finding: During follow-up, 12% of patients had an indication for PsA. Rates of comorbidities like hypertension, hyperlipidemia, fatigue, diabetes, chronic pulmonary disease, obesity, cardiovascular disease, depression, and anxiety were at least 1.1-1.7 times higher in the psoriasis-PsA vs. psoriasis-only group.
Study details: This was a retrospective study of 19,333 patients with prevalent psoriasis with no prior evidence of PsA from the United States.
Disclosures: The study was funded by UCB Pharma. R Suruki and E Lee declared being employees and shareholders of UCB Pharma. M Skornicki, P Prince, and A Louder declared being employees of Aetion Inc.
Source: Skornicki M et al. Adv Ther. 2021 Apr 5. doi: 10.1007/s12325-021-01698-7.